
|Articles|April 15, 2022
Daily Medication Pearl: Ponesimod (Ponvory)
Author(s)Saro Arakelians, PharmD
Ponesimod (Ponvory) is indicated for the treatment of relapsing forms of multiple sclerosis.
Advertisement
Medication Pearl of the Day: Ponesimod (Ponvory)
Indication: Ponesimod (Ponvory) is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.
Insight:
- Dosing: The recommended maintenance dosage is 20 mg taken orally once daily.
- Dosage forms: Tablets 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, and 20 mg.
- Adverse events: Most common adverse reactions (incidence at least 10%) are upper respiratory tract infection, hepatic transaminase elevation, and hypertension.
- Mechanism of action: Ponesimod is a sphingosine 1-phosphate (S1P) receptor 1 modulator that binds with high affinity to S1P receptor 1.
- Manufacturer: Janssen Pharma
Source
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Higher-Dose Semaglutide Achieves Significant Weight Reduction in Adults with Obesity
2
Ethical Considerations of Artificial Intelligence Use Abound
3
The Average Health Insurance Premium Now Costs $27k Per Year for a Family
4
Prevention for Protection: The Evolution of Heart Failure Management
5
















































































































































































































